AngioDynamics, Inc.

NASDAQ:ANGO

Medical - Instruments & Supplies

Healthcare
$11.32 +1.71%

+$0.20 today

Market cap
$476.06M
Beta
0.36
P/E (TTM)
-15.8
EPS (TTM)
-$0.75
52W Low $8.36High $13.99

Volume 0.32M

Average 0.40M

ANGO Net Income

Bottom-line profit, the starting point for calculating cash from operations.

AngioDynamics, Inc.NASDAQ: ANGO

Net Income · Q3 FY2026 · quarter ended Feb 2026

Net income growth accelerates

Q3 FY2026 net income of $8.08M (cash outflow) rose 83.4% year over year, ahead of the -24.2% change in trailing-twelve-month net income. Sequentially, it rose 27.3% from the prior quarter. Over 3 fiscal years it compounded at +8.6% a year.

Context

  • Net income amounted to 11.6% of revenue in FY2025, down 49.0 pp from a year earlier.
  • Net income grew in size in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 3 analysts of -$6.73M (-80.2%) for the fiscal year ending May 2026, a step up from the -81.6% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterFeb 2026
-$8.08M+27.3% QoQ
Last fiscal yearMay 2025
-$33.99M-81.6% YoY
LTMFeb 2026
-$31.39M-24.2% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+83.4%-38.3%-121.8 pp
1 year-81.6%-80.2%+1.4 pp
3-year CAGR+8.6%-50.2%-58.8 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(33.99M) USD
Year-over-year change
+81.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How ANGO compares with its peers on the latest reported figures

  • ANGO's LTM Feb 2026 net income of $31.39M is the smallest of the 9 companies compared; the peer median is $111.26M.
  • Its year-over-year change of -24.2% is the 6th highest of 9, against a peer median of +21.6%.
  • Net income amounts to 10.0% of revenue for ANGO, versus a peer median of 11.5%.
ANGO Competitors Peer median
Net Income for ANGO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BSXBoston Scientific CorporationLTM Jun 2026$3.67B +34.6%+60.6%17.5%
BDXBecton, Dickinson and CompanyLTM Sep 2026$1.22B -27.5%-9.2%6.0%
IARTIntegra LifeSciences Holdings CorporationLTM Mar 2026$495.8M +1612.2%—30.1%
TFXTeleflex IncorporatedLTM Jun 2026$320.9M -267.2%-45.6%12.3%
PENPenumbra, Inc.LTM Jun 2026$160.59M +8.7%—10.7%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$160.12M +35.2%+19.9%9.9%
LMATLeMaitre Vascular, Inc.LTM Mar 2026$62.4M +38.2%+40.9%24.3%
CNMDCONMED CorporationLTM Mar 2026$54.85M -53.8%—4.0%
ANGOAngioDynamics, Inc.LTM Feb 2026$31.39M -24.2%+8.6%10.0%
Peer median (excluding ANGO) $111.26M+21.6%+19.9%11.5%

Competitors are the stored peer set for ANGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
May 2021
FY2022
May 2022
FY2023
May 2023
FY2024
May 2024
FY2025
May 2025
Net Income(31.55M)(26.55M)(52.44M)(184.35M)(33.99M)
Depreciation & Amortization25.92M29.35M30.87M27.71M25.8M
Deferred Income Tax(4.81M)(3.71M)(2.31M)(7.97M)(988K)
Stock-Based Compensation8.63M10.69M11.16M10.53M9.77M
Change in Working Capital9.07M(21.05M)(7.03M)14.42M(14.11M)
Accounts Receivables(4.16M)(17.15M)(1.3M)7.89M23K
Inventory11.54M(2.8M)(8.2M)(9.41M)(1.35M)
Accounts Payables4.88M3.91M2.14M27.53M(15.88M)
Other Working Capital(3.18M)(5.01M)332K(11.59M)3.09M
Other Non-Cash Items16.83M4.07M19.83M111.5M3.39M
Operating Cash Flow24.09M(7.19M)78K(28.16M)(10.13M)
Capital Expenditures(5.19M)(4.3M)(4.35M)(5.77M)(4.46M)
Acquisitions (Net)0(3.6M)000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(8.52M)(11.41M)(5.93M)126.24M(5.71M)
Investing Cash Flow(13.71M)(19.31M)(9.75M)123.72M(10.18M)
Debt Repayment(20M)5M25M(50M)6.16M
Common Stock Issued3.01M2.68M1.17M752K0
Common Stock Repurchased0000(1.67M)
Dividends Paid00000
Other Financing Activities00(751K)(15M)(4.75M)
Financing Cash Flow(16.99M)7.68M25.42M(64.25M)(255K)
Effect of Forex Changes330K(518K)43K125K398K
Net Change in Cash(6.27M)(19.34M)15.8M31.44M(20.16M)
Free Cash Flow18.91M(11.49M)(4.27M)(33.93M)(14.59M)

AngioDynamics, Inc.

NASDAQ:ANGO

Intrinsic Alpha fair value

Locked

Current Price

$11.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.